U.S. Markets closed
  • S&P 500

    4,544.90
    -4.88 (-0.11%)
     
  • Dow 30

    35,677.02
    +73.94 (+0.21%)
     
  • Nasdaq

    15,090.20
    -125.50 (-0.82%)
     
  • Russell 2000

    2,291.27
    -4.91 (-0.21%)
     
  • Gold

    1,793.10
    +11.20 (+0.63%)
     
  • EUR/USD

    1.1648
    +0.0018 (+0.1514%)
     
  • 10-Yr Bond

    1.6550
    -0.0210 (-1.25%)
     
  • Vix

    15.43
    +0.42 (+2.80%)
     
  • GBP/USD

    1.3759
    -0.0036 (-0.2628%)
     
  • USD/JPY

    113.4600
    -0.5280 (-0.4632%)
     
  • BTC-USD

    61,182.04
    -1,800.06 (-2.86%)
     
  • CMC Crypto 200

    1,453.34
    -49.70 (-3.31%)
     
  • FTSE 100

    7,204.55
    +14.25 (+0.20%)
     
  • Nikkei 225

    28,804.85
    +96.25 (+0.34%)
     

Top Stock Reports for Abbott, Intel & QUALCOMM

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Thursday, September 9, 2021

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), Intel Corporation (INTC), and QUALCOMM Incorporated (QCOM). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of Abbott have outperformed the Zacks Medical Products industry in the year to date period (+18.7% vs. +9%). The Zacks analyst believes that momentum in the branded generics and international diabetes businesses is likely to drive growth in the coming quarters.

Abbott posted better-than-expected earnings and revenue numbers for the second quarter of 2021. The company registered organic sales growth across each operating segment. Improved demands for routine diagnostic testing drove the Underlying Diagnostics sales in the quarter. Mass vaccination and a steady decline in new cases in the past few months, however, has led to a significant reduction in COVID-19 testing sales.

(You can read the full research report on Abbott here >>>)

Intel shares have lost -12.6% in the past six months against the Zacks General Semiconductor industry’s gain of +32.5%, however, it has been riding on robust performance of its client computing group (CCG) business. The Zacks analyst believes that Intel’s leading position in PC market, strength in servers, growing clout in software, IoT & ADAS domains and headway in process technology are positive indicators of future growth prospects.

Intel is likely to benefit from higher demand for its 10 nanometer (nm) SuperFin process-based 11th Gen core processors, due to continuation of remote working and online learning wave. Stiff competition from ARM-based devices, and impact of new product costs, however, are major concerns amid significant foreign currency exposure. Production delays pertaining to 7 nm ramp up is another major headwind.

(You can read the full research report on Intel here >>>)

Shares of QUALCOMM have gained +7.1% in the last three months against the Zacks Wireless Equipment industry’s gain of +4.1%. The Zacks analyst believes that Qualcomm is likely to benefit from solid 5G traction with greater long-term visibility.

The company has upped the ante with the launch of the first-of-its-kind automotive platform, Snapdragon Ride, and is on track to deliver $10 billion in annual revenues as the business continues to diversify. Healthy traction in EDGE networking, as well as robust automotive telematics and connectivity platforms, is a positive. It is, however, susceptible to risks arising from a decline in handset shipments.

(You can read the full research report on QUALCOMM here >>>)

Other noteworthy reports we are featuring today include Shopify Inc. (SHOP), Bristol-Myers Squibb Company (BMY) and The TJX Companies, Inc. (TJX).

Sheraz Mian

Director of Research

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Intel Corporation (INTC) : Free Stock Analysis Report
 
Abbott Laboratories (ABT) : Free Stock Analysis Report
 
QUALCOMM Incorporated (QCOM) : Free Stock Analysis Report
 
Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report
 
The TJX Companies, Inc. (TJX) : Free Stock Analysis Report
 
Shopify Inc. (SHOP) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research